Report Highlights

Urology Devices in the U.S.: Market Overview

The U.S. urology devices market generated an estimated USD 9.6 billion in 2024, making it the largest national urology device market globally and roughly 45 percent of worldwide spend. Its structure reflects regulatory and payment policy more than clinical demand. Procedure volumes for benign prostatic hyperplasia, kidney stones, urinary incontinence and prostate cancer are high, but product categories have consolidated around devices that fit Medicare's ambulatory and outpatient payment classifications. Private manufacturers led innovation in robotic and endoscopic platforms, while government agencies set the terms of adoption.

Government has been the dominant force in pricing and access, while the private sector has led on product design. The Centers for Medicare and Medicaid Services (CMS) sets Medicare payment through the Hospital Outpatient Prospective Payment System and the Physician Fee Schedule, and those rates determine which devices hospitals can afford. The FDA's Center for Devices and Radiological Health controls market entry. Private firms such as Boston Scientific and Coloplast supply most disposables, while Intuitive Surgical leads capital robotics.

Policy-Driven Growth in U.S. Urology Devices

The first mechanism is the 21st Century Cures Act of 2016, whose Section 3052 created the FDA Breakthrough Devices Program. Designated urology devices, such as prostate-targeted therapies and bladder monitoring systems, receive priority interaction and faster review, cutting time to market and accelerating commercial launch. The second is CMS's Transitional Coverage for Emerging Technologies (TCET) Final Notice, published in August 2024, which provides up to five years of coverage for designated breakthrough devices and converts launch risk into reimbursed volume for manufacturers.

The third mechanism is the outpatient shift. CMS's Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Covered Procedures List, updated annually in the Outpatient and Physician Fee Schedule rules, have moved transurethral resection of the prostate and ureteroscopy for kidney stones into lower-cost settings. Manufacturers of single-use endoscopes, laser fibres and lithotripsy consumables gain volume as ambulatory surgery centres adopt them. Each procedure reclassified to an ASC payment rate widens the addressable base for disposable urology devices.

Regulatory Barriers and Compliance Costs

Market entry is administered by the FDA's Center for Devices and Radiological Health under the Federal Food, Drug, and Cosmetic Act. A 510(k) premarket notification carries an FDA performance goal of 90 review days, but standard user fees exceed USD 20,000 per submission. A premarket approval for higher-risk urology devices carries a 180-day review goal and substantially higher cost. The Quality System Regulation at 21 CFR Part 820 is being amended to incorporate ISO 13485:2016, effective 2 February 2026, forcing manufacturers to re-audit supplier controls.

Compliance cost compounds at the commercial layer. The Physician Payments Sunshine Act, codified at Section 1128G of the Social Security Act and administered by CMS through Open Payments, requires manufacturers to report payments to urologists, and the Anti-Kickback Statute enforced by the HHS Office of Inspector General restricts bundled rebates. Unique Device Identification requirements under 21 CFR Part 830, enforced by FDA, mandate GUDID labelling and add per-SKU data costs. Section 301 duties on China-origin urology catheters and components, collected by U.S. Customs and Border Protection, raise landed cost for smaller importers.

Policy-Created Opportunities in the U.S.

The first opportunity sits in Medicare Transitional Pass-Through payment for devices under Section 1833(t)(6) of the Social Security Act, which provides supplemental payment for approved devices for at least two years and up to three. Urology manufacturers with novel stone-treatment or incontinence devices can secure this add-on payment, which offsets hospital acquisition costs and accelerates adoption. The second is the VA National Acquisition Center's Federal Supply Schedule, which allows urology suppliers to bid on Veterans Health Administration volumes, where Trade Agreements Act compliance is a condition of award.

The third opportunity lies in outpatient ASC migration. As CMS phases procedures off the Inpatient Only list, ambulatory surgery centres will require lower-cost single-use kits and capital systems that fit ASC payment rates, a segment currently served mainly by Coloplast and Cook Medical. Manufacturers that design for ASC throughput, with pre-packaged ureteroscopy and cystoscopy kits, capture volume where hospital capital budgets are not the constraint. Early contracts with ASC operators secure volume before pricing matures.

Market at a Glance

Leading Market Participants

• Intuitive Surgical
• Boston Scientific
• Coloplast
• Teleflex
• Becton Dickinson
• Cook Medical
• Laborie
• Olympus
• Medtronic
• Karl Storz

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, Chapter V, Medical Devices, with user fee authority conferred by the Medical Device User Fee Amendments, reauthorised as MDUFA V for fiscal years 2023 through 2027. FDA's Center for Devices and Radiological Health administers premarket clearance and approval, while CMS administers reimbursement and the HHS Office of Inspector General enforces fraud and abuse law. Key compliance obligations include 21 CFR Part 820 quality systems, 21 CFR Part 830 Unique Device Identification, Medical Device Reporting under 21 CFR Part 803, and Open Payments under Section 1128G of the Social Security Act.

Regulatory change is accelerating. The amended Quality System Regulation, incorporating ISO 13485:2016, takes effect on 2 February 2026. MDUFA VI negotiations, covering fiscal years 2028 through 2032, will conclude with commitment letters sent to Congress in early 2027. Compared with regional peers, the U.S. regime is faster to market than the EU Medical Device Regulation (Regulation (EU) 2017/745), which requires notified-body review, while Japan's PMDA and China's NMPA demand local clinical data that U.S. approval does not.

Long-Term Policy Outlook for U.S. Urology Devices

By 2032, the most consequential shift will be payment, not approval. The inpatient-only list phase-out will move a larger share of urology procedures to ASCs and office settings, and CMS will extend site-neutral payment principles across outpatient services. MDUFA VI will set FDA review resources through fiscal 2032. TCET coverage will expand as breakthrough urology devices move from designation to coverage determinations, reshaping which manufacturers secure reimbursed volume.

Suppliers will face consolidation pressure. Single-use consumables will remain profitable only where manufacturers hold pass-through status or ASC-optimised kits. Expect tighter Section 301 duty regimes on China-origin components, pushing sourcing toward Mexico under USMCA and Ireland within EU supply chains. Compliance cost will rise as QMSR audits, UDI data and Open Payments reporting converge, favouring Boston Scientific, Olympus and Teleflex, which can spread fixed compliance overhead across broad portfolios.